Jefferson Bridge Capital LLC Acquires Shares of 52,798 Harrow, Inc. $HROW

Jefferson Bridge Capital LLC acquired a new stake in Harrow, Inc. (NASDAQ:HROW) in the fourth quarter, Holdings Channel reports. The institutional investor acquired 52,798 shares of the company’s stock, valued at approximately $2,587,000. Harrow makes up approximately 2.6% of Jefferson Bridge Capital LLC’s investment portfolio, making the stock its 14th largest position.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HROW. Royal Bank of Canada increased its holdings in Harrow by 102.5% in the first quarter. Royal Bank of Canada now owns 9,813 shares of the company’s stock valued at $261,000 after buying an additional 4,967 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Harrow by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company’s stock worth $483,000 after purchasing an additional 790 shares in the last quarter. Strs Ohio purchased a new stake in shares of Harrow during the first quarter worth about $149,000. Legal & General Group Plc increased its stake in shares of Harrow by 12.4% during the second quarter. Legal & General Group Plc now owns 30,753 shares of the company’s stock worth $939,000 after purchasing an additional 3,384 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in shares of Harrow by 9.3% during the second quarter. Rhumbline Advisers now owns 46,969 shares of the company’s stock worth $1,434,000 after purchasing an additional 3,994 shares in the last quarter. Hedge funds and other institutional investors own 72.76% of the company’s stock.

Harrow Stock Performance

NASDAQ:HROW opened at $35.43 on Wednesday. The company has a debt-to-equity ratio of 4.67, a current ratio of 2.20 and a quick ratio of 2.06. The firm has a market capitalization of $1.32 billion, a price-to-earnings ratio of -208.40 and a beta of 0.31. The company’s 50-day moving average is $41.75 and its two-hundred day moving average is $43.05. Harrow, Inc. has a 1-year low of $20.85 and a 1-year high of $54.85.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Zacks Research raised shares of Harrow from a “strong sell” rating to a “hold” rating in a research note on Friday, April 3rd. BTIG Research reissued a “buy” rating and set a $63.00 target price on shares of Harrow in a research note on Wednesday, March 18th. HC Wainwright reissued a “buy” rating and set a $70.00 target price on shares of Harrow in a research note on Thursday, March 19th. Nomura cut shares of Harrow to a “neutral” rating in a research note on Wednesday, March 18th. Finally, B. Riley Financial reissued a “buy” rating and set a $65.00 target price (down from $74.00) on shares of Harrow in a research note on Tuesday. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $69.86.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.